TY - JOUR T1 - Dantrolene Requires Mg<sup>2+</sup> and ATP To Inhibit the Ryanodine Receptor JF - Molecular Pharmacology JO - Mol Pharmacol SP - 401 LP - 407 DO - 10.1124/mol.119.116475 VL - 96 IS - 3 AU - Gyula Diszházi AU - Zsuzsanna Édua Magyar AU - János András Mótyán AU - László Csernoch AU - István Jóna AU - Péter Pál Nánási AU - János Almássy Y1 - 2019/09/01 UR - http://molpharm.aspetjournals.org/content/96/3/401.abstract N2 - Dantrolene is a ryanodine receptor (RyR) inhibitor, which is used to relax muscles in malignant hyperthermia syndrome. Although dantrolene binds to the RyR protein, its mechanism of action is unknown, mainly because of the controversial results showing that dantrolene inhibited Ca2+ release from intact fibers and sarcoplasmic reticulum (SR) vesicles, but failed to inhibit single RyR channel currents in bilayers. Accordingly, it was concluded that an important factor for dantrolene’s action was lost during the purification procedure of RyR. Recently, Mg2+ was demonstrated to be the essential factor for dantrolene to inhibit Ca2+ release in skinned muscle fibers. The aim of the present study was to confirm these results in Ca2+ release and bilayer experiments, using SR vesicles and solubilized channels, respectively. Our Ca2+ release experiments demonstrated that the effect of dantrolene and Mg2+ was cooperative and that ATP enhanced the inhibiting effect of dantrolene. Namely, 10 µM dantrolene reduced RyR channel open probability by ∼50% in the presence of 3 mM free Mg2+ and 1 mM ATP, whereas channel activity further decreased to ∼20% of control when [ATP] was increased to 2 mM. Our data provide important complementary information that supports the direct, Mg2+-dependent mechanism of dantrolene’s action and suggests that dantrolene also requires ATP to inhibit RyR. ER -